Multi-Chamber Blister Package Protects Without Cool Storage
The Multi-Chamber Blister System is a blister package that incorporates Amcor's SafeMix cold form laminate to transport vaccines and sensitive APIs without the need for cool storage.
Medicines and vaccines with unstable and moisture-sensitive ingredients can now be transported in one pack, safely and without cool storage, with technology developed by Amcor and Rohrer-Leading Solutions. The Multi-Chamber Blister System is a pharmaceutical blister that incorporates Amcor’s SafeMix cold form laminate. One chamber can be filled with a dry powder incorporating an active ingredient, and the other with a liquid. A frangible seal, once peeled, opens a channel between the chambers and the components are mixed by pushing on the cavities.
The pack enhances drug stability and simplifies the supply chain by eliminating cool storage and glass containers. SafeMix can also be used for diagnostics in situations where a complex laboratory environment cannot be set up. The system represents a new way to transport vaccines or sensitive APIs.
Source: Amcor Flexibles
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
